BR112017004446A2 - anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer - Google Patents

anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer

Info

Publication number
BR112017004446A2
BR112017004446A2 BR112017004446-3A BR112017004446A BR112017004446A2 BR 112017004446 A2 BR112017004446 A2 BR 112017004446A2 BR 112017004446 A BR112017004446 A BR 112017004446A BR 112017004446 A2 BR112017004446 A2 BR 112017004446A2
Authority
BR
Brazil
Prior art keywords
cancer
finding
specific antibody
test method
target molecule
Prior art date
Application number
BR112017004446-3A
Other languages
English (en)
Japanese (ja)
Inventor
Matsumura Yasuhiro
Yasunaga Masahiro
Saijou Shinji
Hanaoka Shingo
Original Assignee
National Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Cancer Center filed Critical National Cancer Center
Publication of BR112017004446A2 publication Critical patent/BR112017004446A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)

Abstract

resumo ?anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer? um objetivo da presente invenção consiste em proporcionar um fármaco anticâncer capaz de tratar câncer encontrando-se uma molécula alvo especificamente expressada em células cancerígenas e atuando-se especificamente sobre a molécula alvo, e proporcionar um método de teste para constatação de câncer incluindo uma etapa de medir a molécula alvo em uma amostra. a presente invenção proporciona um fármaco anticâncer contendo, como um ingrediente ativo do mesmo, um anticorpo 180 (tmem-180) de proteína anti-transmembranar ou um fragmento de ligação ao antígeno do mesmo. além disso, a presente invenção proporciona um método de teste para constatação de câncer incluindo uma etapa para medir a quantidade de tmem-180 em uma amostra coletada a partir de um indivíduo.
BR112017004446-3A 2014-09-08 2015-09-08 anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer BR112017004446A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2014-182760 2014-09-08
JP2014182760 2014-09-08
JP2014-260727 2014-12-24
JP2014260727 2014-12-24
PCT/JP2015/075425 WO2016039321A1 (ja) 2014-09-08 2015-09-08 がん細胞特異的な抗体、抗がん剤、及びがんの検査方法

Publications (1)

Publication Number Publication Date
BR112017004446A2 true BR112017004446A2 (pt) 2018-02-27

Family

ID=55459067

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017004446-3A BR112017004446A2 (pt) 2014-09-08 2015-09-08 anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer

Country Status (13)

Country Link
US (2) US10471146B2 (pt)
EP (1) EP3192527A4 (pt)
JP (2) JP6781507B2 (pt)
KR (1) KR102029248B1 (pt)
CN (1) CN106999576B (pt)
AU (2) AU2015313268B2 (pt)
BR (1) BR112017004446A2 (pt)
CA (1) CA2960466C (pt)
IL (1) IL250848B (pt)
MY (1) MY187050A (pt)
RU (1) RU2753512C2 (pt)
SG (1) SG11201701809UA (pt)
WO (1) WO2016039321A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11633499B2 (en) 2016-03-08 2023-04-25 National Cancer Center Japan Anti-TMEM-180 antibody, anticancer drug and cancer testing method
JP7209284B2 (ja) 2016-08-15 2023-01-20 国立研究開発法人国立がん研究センター Ｔｍｅｍ１３２ａに結合する抗体、抗がん剤、およびがんの検査方法
JP6782949B2 (ja) * 2017-03-31 2020-11-11 株式会社Ｈｉｒｏｔｓｕバイオサイエンス がん患者の治療効果の予測および／または再発モニタリング
GB201710838D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710836D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
GB201710835D0 (en) 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
KR20200106498A (ko) * 2018-01-05 2020-09-14 이뮤넥스트, 인크. 항-mct1 항체 및 그의 용도
US20220389088A1 (en) * 2019-10-29 2022-12-08 University Of Florida Research Foundation, Incorporated Anti-angiopoietin-like 4 (angptl4) antibodies and methods of use
WO2022098662A2 (en) * 2020-11-03 2022-05-12 Twist Bioscience Corporation Methods and compositions relating to chemokine receptor variants
WO2023105087A1 (en) * 2021-12-10 2023-06-15 Tubulis Gmbh Novel flt3 antibodies and antibody-drug-conjugates based thereon, therapeutic methods and uses thereof in combination with tyrosine kinase inhibitors
CN117567635B (zh) * 2024-01-16 2024-05-14 恺佧生物科技(上海)有限公司 抗Cas9酶的抗体及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009045201A1 (en) * 2006-08-02 2009-04-09 Biogen Idec Ma Inc. Cancer stem cells
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
KR20110084196A (ko) * 2008-09-26 2011-07-21 유레카 쎄라퓨틱스, 인코포레이티드 다양한 글리코실화 패턴을 가진 세포계 및 단백질
EP2177615A1 (en) * 2008-10-10 2010-04-21 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
WO2010111198A1 (en) 2009-03-23 2010-09-30 Quark Pharmaceuticals, Inc. Compounds compositions and methods of treating cancer and fibrotic diseases
US20110195848A1 (en) * 2010-01-08 2011-08-11 Roopra Avtar S Gene expression and breast cancer
WO2012045481A2 (en) * 2010-10-05 2012-04-12 Daiichi Sankyo Company, Limited Antibody targeting osteoclast-related protein siglec-15
WO2013133450A1 (ja) * 2012-03-06 2013-09-12 株式会社バイオマトリックス研究所 がん治療用医薬組成物
US20150226744A1 (en) * 2012-09-17 2015-08-13 Ait Austrian Institute Of Technology Gmbh Colon Cancer Diagnostic Method and Means
US11633499B2 (en) * 2016-03-08 2023-04-25 National Cancer Center Japan Anti-TMEM-180 antibody, anticancer drug and cancer testing method

Also Published As

Publication number Publication date
WO2016039321A1 (ja) 2016-03-17
CN106999576B (zh) 2021-09-03
AU2018274932B2 (en) 2020-11-05
RU2753512C2 (ru) 2021-08-17
AU2018274932A1 (en) 2019-01-03
JP2021019616A (ja) 2021-02-18
EP3192527A1 (en) 2017-07-19
IL250848A0 (en) 2017-04-30
JPWO2016039321A1 (ja) 2017-06-22
JP6980075B2 (ja) 2021-12-15
CN106999576A (zh) 2017-08-01
RU2017111584A3 (pt) 2018-10-10
CA2960466A1 (en) 2016-03-17
EP3192527A4 (en) 2018-04-11
US10471146B2 (en) 2019-11-12
AU2015313268B2 (en) 2018-12-20
KR102029248B1 (ko) 2019-10-08
RU2017111584A (ru) 2018-10-10
JP6781507B2 (ja) 2020-11-04
MY187050A (en) 2021-08-27
CA2960466C (en) 2023-09-05
US11524074B2 (en) 2022-12-13
SG11201701809UA (en) 2017-04-27
IL250848B (en) 2022-07-01
KR20170047351A (ko) 2017-05-04
AU2015313268A1 (en) 2017-03-23
US20200078458A1 (en) 2020-03-12
US20170260284A1 (en) 2017-09-14

Similar Documents

Publication Publication Date Title
BR112017004446A2 (pt) anticorpo específico a células cancerígenas, fármaco anticâncer e método de teste para constatação de câncer
BR112019006106A2 (pt) formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio.
BR112018010933A2 (pt) anticorpos multiespecíficos
BR112018005164A2 (pt) anticorpos, ácido nucleico, célula hospedeira, método para produzir um anticorpo, formulação farmacêutica, uso do anticorpo e método de tratamento de um indivíduo que tem câncer
BR112018069849A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático precoce ou de lesão precursora do câncer pancreático
AR113142A1 (es) Moléculas de unión al antígeno multiespecíficas que tienen actividad de sustitución de la función de cofactor del factor viii de coagulación de sangre (fviii), y formulaciones farmacéuticas que contienen dicha molécula como ingrediente activo
BR112017004899A2 (pt) detecção de proteínas mal dobradas
BR112017017025A2 (pt) métodos e composições para analizar componentes celulares
BR112016015677A2 (pt) Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica
BR112016027475A2 (pt) kit, dispositivo e método para a detecção de câncer pancreático
BR112015022019A2 (pt) Anticorpos isolados, ácido nucleico, célula hospedeira, método de produção de anticorpos, imunoconjugado, formulação farmacêutica, métodos de tratamento de indivíduos, de inibição da proliferação de células, de detecção de b7-h4 humano e de detecção de câncer
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
WO2015011282A3 (en) Method for identifying modulators of bcrp/abcg2-mediated atp release and use of said modulators for treating diseases
BR112019018685A8 (pt) Anticorpos, composição farmacêutica, kit, usos de um anticorpo e método in vitro de identificação ou seleção de um anticorpo
BR112016029583A2 (pt) ?kit ou dispositivo para a detecção de câncer esofágico e método de detecção?
UA117364C2 (uk) Похідні аматоксину
BR112017004631A2 (pt) anticorpo, ácido nucleico, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos de tratamento, de inibição da proliferação de uma célula e de detecção de her2 humana e método para a detecção de um câncer
BR112016008146A2 (pt) Anticorpo isolado, ácido nucleico isolado, célula hospedeira, método de produção de um anticorpo, imunoconjugado, formulação farmacêutica, métodos para detectar um câncer, de identificação e de seleção de um paciente com câncer
AR093377A1 (es) Anticuerpos anti-notch y conjugados de anticuerpo-farmaco
BR112018017168A2 (pt) emplastro de coloração do sangue, método e dispositivo para teste sanguíneo usando o mesmo
BR112013001410A2 (pt) aparelhos biossensores e métodos dos mesmos
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
BR112018015965A2 (pt) método para determinação de helicobacter pylori
BR112016024421A2 (pt) composição farmacêutica, cápsula e uso da composição farmacêutica
BR112016028496A2 (pt) análise quantitativa de proteínas transgênicas

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]